1. Wei, Chuan-Yuan, Zhu, Meng-Xuan, Zhang, Peng-Fei, Ke, Ai-Wu, Fan, Jia. 2022. PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma. In Journal of hepatology, 77, 163-176. doi:10.1016/j.jhep.2022.02.019. https://pubmed.ncbi.nlm.nih.gov/35219791/
2. Zhu, Mengxuan, Zhang, Pengfei, Yu, Shan, Liu, Tianshu, Cui, Yuehong. 2022. Targeting ZFP64/GAL-1 axis promotes therapeutic effect of nab-paclitaxel and reverses immunosuppressive microenvironment in gastric cancer. In Journal of experimental & clinical cancer research : CR, 41, 14. doi:10.1186/s13046-021-02224-x. https://pubmed.ncbi.nlm.nih.gov/34996504/
3. Sun, Jiayi, Liu, Jinquan, Hou, Yudong, Ye, Yan, Liu, Jintao. 2024. ZFP64 drives glycolysis-mediated stem cell-like properties and tumorigenesis in breast cancer. In Biology direct, 19, 83. doi:10.1186/s13062-024-00533-7. https://pubmed.ncbi.nlm.nih.gov/39294751/
4. Lu, Bin, Klingbeil, Olaf, Tarumoto, Yusuke, Shi, Junwei, Vakoc, Christopher R. 2018. A Transcription Factor Addiction in Leukemia Imposed by the MLL Promoter Sequence. In Cancer cell, 34, 970-981.e8. doi:10.1016/j.ccell.2018.10.015. https://pubmed.ncbi.nlm.nih.gov/30503706/
5. Sakamoto, Kei, Tamamura, Yoshihiro, Katsube, Ken-ichi, Yamaguchi, Akira. 2008. Zfp64 participates in Notch signaling and regulates differentiation in mesenchymal cells. In Journal of cell science, 121, 1613-23. doi:10.1242/jcs.023119. https://pubmed.ncbi.nlm.nih.gov/18430783/
6. Zhang, KeJing, Guo, Lei, Li, Xin, Hu, Yu, Luo, Na. 2025. Cancer-associated fibroblasts promote doxorubicin resistance in triple-negative breast cancer through enhancing ZFP64 histone lactylation to regulate ferroptosis. In Journal of translational medicine, 23, 247. doi:10.1186/s12967-025-06246-3. https://pubmed.ncbi.nlm.nih.gov/40022222/
智鼠故事 
